The Real-world Treatment Satisfaction by Gefapixiant in Patients with Refractory Chronic Cough in Terms of Cough Improvement and Taste Disturbance (The RESTORE Study)

What this Trial Is About

Researchers are evaluating gefapixant, a P2X3 receptor antagonist, for patients with refractory chronic cough (RCC), a condition where cough persists despite usual treatments. This study aims to understand how taste disturbances caused by gefapixant relate to improvements in cough-specific quality of life and overall treatment satisfaction. Additionally, the study will explore potential biomarkers to help predict which patients respond well to gefapixant. Participants will receive 45 mg of gefapixant twice daily for 12 weeks. The study focuses on real-world clinical use and investigates the relationship between taste changes and cough improvement. Researchers will monitor treatment satisfaction, changes in cough-related quality of life, alterations in taste perception, and seek biomarkers during the treatment period. During the trial, participants will be assessed at 12 weeks for treatment satisfaction, changes in cough-specific quality of life, taste changes, and potential biomarkers. The study will include questionnaires and clinical evaluations to track these outcomes. The total participation covers the 12-week treatment period, with data collection focused on understanding how taste disturbances impact patient experience and cough improvement.

The Real-world Treatment Satisfaction by Gefapixiant in RCC